Foghorn Therapeutics Inc (FHTX) USD0.0001
Foghorn Therapeutics Inc. is focused on the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. It is initially focused on oncology. It is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The Company is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.